Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

Thomas J. Herzog; Sandro Pignata; Sharad A. Ghamande; Maria-Jesús Rubio; Keiichi Fujiwara; Christof Vulsteke; Deborah K. Armstrong; Jalid Sehouli; Robert L. Coleman; Hani Gabra; Giovanni Scambia; Bradley J. Monk; José A. Arranz; Kimio Ushijima; Rabbie Hanna; Claudio Zamagni; Robert M. Wenham; Antionio González-Martín; Brian Slomovitz; Yan Jia; Lisa Ramsay; Krishnansu S. Tewari; Susan C. Weil; Ignace B. Vergote

doi:10.1016/j.ygyno.2023.01.003

Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

Thomas J. Herzog, Sandro Pignata, Sharad A. Ghamande, Maria-Jesús Rubio, Keiichi Fujiwara, Christof Vulsteke, Deborah K. Armstrong, Jalid Sehouli, Robert L. Coleman, Hani Gabra, Giovanni Scambia, Bradley J. Monk, José A. Arranz, Kimio Ushijima, Rabbie Hanna, Claudio Zamagni, Robert M. Wenham, Antionio González-Martín, Brian Slomovitz, Yan JiaLisa Ramsay, Krishnansu S. Tewari, Susan C. Weil, Ignace B. Vergote

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Lingua originale	English
pagine (da-a)	300-308
Numero di pagine	9
Rivista	Gynecologic Oncology
DOI	https://doi.org/10.1016/j.ygyno.2023.01.003
Stato di pubblicazione	Pubblicato - 2023

Keywords

Farletuzumab
Folate receptor-α
Progression-free survival
Ovarian cancer
MORAb-003

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/j.ygyno.2023.01.003

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Herzog, T. J., Pignata, S., Ghamande, S. A., Rubio, M.-J., Fujiwara, K., Vulsteke, C., Armstrong, D. K., Sehouli, J., Coleman, R. L., Gabra, H., Scambia, G., Monk, B. J., Arranz, J. A., Ushijima, K., Hanna, R., Zamagni, C., Wenham, R. M., González-Martín, A., Slomovitz, B., ... Vergote, I. B. (2023). Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer. Gynecologic Oncology, 300-308. https://doi.org/10.1016/j.ygyno.2023.01.003

@article{fdc44451785242bea44e9ed1ff148627,

title = "Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer",

keywords = "Farletuzumab, Folate receptor-α, Progression-free survival, Ovarian cancer, MORAb-003, Farletuzumab, Folate receptor-α, Progression-free survival, Ovarian cancer, MORAb-003",

author = "Herzog, {Thomas J.} and Sandro Pignata and Ghamande, {Sharad A.} and Maria-Jes{\'u}s Rubio and Keiichi Fujiwara and Christof Vulsteke and Armstrong, {Deborah K.} and Jalid Sehouli and Coleman, {Robert L.} and Hani Gabra and Giovanni Scambia and Monk, {Bradley J.} and Arranz, {Jos{\'e} A.} and Kimio Ushijima and Rabbie Hanna and Claudio Zamagni and Wenham, {Robert M.} and Antionio Gonz{\'a}lez-Mart{\'i}n and Brian Slomovitz and Yan Jia and Lisa Ramsay and Tewari, {Krishnansu S.} and Weil, {Susan C.} and Vergote, {Ignace B.}",

year = "2023",

doi = "10.1016/j.ygyno.2023.01.003",

language = "English",

pages = "300--308",

journal = "Gynecologic Oncology",

issn = "1095-6859",

publisher = "Academic Press Inc.",

}

Herzog, TJ, Pignata, S, Ghamande, SA, Rubio, M-J, Fujiwara, K, Vulsteke, C, Armstrong, DK, Sehouli, J, Coleman, RL, Gabra, H, Scambia, G, Monk, BJ, Arranz, JA, Ushijima, K, Hanna, R, Zamagni, C, Wenham, RM, González-Martín, A, Slomovitz, B, Jia, Y, Ramsay, L, Tewari, KS, Weil, SC & Vergote, IB 2023, 'Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer', Gynecologic Oncology, pagg. 300-308. https://doi.org/10.1016/j.ygyno.2023.01.003

TY - JOUR

T1 - Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

AU - Herzog, Thomas J.

AU - Pignata, Sandro

AU - Ghamande, Sharad A.

AU - Rubio, Maria-Jesús

AU - Fujiwara, Keiichi

AU - Vulsteke, Christof

AU - Armstrong, Deborah K.

AU - Sehouli, Jalid

AU - Coleman, Robert L.

AU - Gabra, Hani

AU - Scambia, Giovanni

AU - Monk, Bradley J.

AU - Arranz, José A.

AU - Ushijima, Kimio

AU - Hanna, Rabbie

AU - Zamagni, Claudio

AU - Wenham, Robert M.

AU - González-Martín, Antionio

AU - Slomovitz, Brian

AU - Jia, Yan

AU - Ramsay, Lisa

AU - Tewari, Krishnansu S.

AU - Weil, Susan C.

AU - Vergote, Ignace B.

PY - 2023

Y1 - 2023

KW - Farletuzumab

KW - Folate receptor-α

KW - Progression-free survival

KW - Ovarian cancer

KW - MORAb-003

KW - Farletuzumab

KW - Folate receptor-α

KW - Progression-free survival

KW - Ovarian cancer

KW - MORAb-003

UR - http://hdl.handle.net/10807/230638

U2 - 10.1016/j.ygyno.2023.01.003

DO - 10.1016/j.ygyno.2023.01.003

M3 - Article

SN - 1095-6859

SP - 300

EP - 308

JO - Gynecologic Oncology

JF - Gynecologic Oncology

ER -